NASDAQ:ITCI - Intra-Cellular Therapies Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $20.45 +0.05 (+0.25 %) (As of 07/17/2018 04:00 PM ET)Previous Close$20.40Today's Range$20.27 - $20.7752-Week Range$10.25 - $25.82Volume327,800 shsAverage Volume454,092 shsMarket Capitalization$1.12 billionP/E Ratio-9.65Dividend YieldN/ABeta0.75 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease. It is also developing ITI-214 for Parkinson's disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York. Receive ITCI News and Ratings via Email Sign-up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:ITCI CUSIPN/A Webwww.intracellulartherapies.com Phone646-440-9333 Debt Debt-to-Equity RatioN/A Current Ratio22.55 Quick Ratio22.55 Price-To-Earnings Trailing P/E Ratio-9.65 Forward P/E Ratio-6.07 P/E GrowthN/A Sales & Book Value Annual Sales$250,000.00 Price / Sales4,474.46 Cash FlowN/A Price / CashN/A Book Value$8.33 per share Price / Book2.45 Profitability EPS (Most Recent Fiscal Year)($2.12) Net Income$-97,770,000.00 Net Margins-39,745.53% Return on Equity-27.67% Return on Assets-26.57% Miscellaneous Employees49 Outstanding Shares54,700,000Market Cap$1,117.99 Intra-Cellular Therapies (NASDAQ:ITCI) Frequently Asked Questions What is Intra-Cellular Therapies' stock symbol? Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI." How were Intra-Cellular Therapies' earnings last quarter? Intra-Cellular Therapies Inc (NASDAQ:ITCI) issued its quarterly earnings data on Thursday, May, 3rd. The biopharmaceutical company reported ($0.65) EPS for the quarter, topping analysts' consensus estimates of ($0.66) by $0.01. Intra-Cellular Therapies had a negative net margin of 39,745.53% and a negative return on equity of 27.67%. View Intra-Cellular Therapies' Earnings History. When is Intra-Cellular Therapies' next earnings date? Intra-Cellular Therapies is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Intra-Cellular Therapies. What price target have analysts set for ITCI? 10 equities research analysts have issued twelve-month target prices for Intra-Cellular Therapies' shares. Their predictions range from $24.00 to $36.00. On average, they anticipate Intra-Cellular Therapies' stock price to reach $29.10 in the next twelve months. This suggests a possible upside of 42.3% from the stock's current price. View Analyst Ratings for Intra-Cellular Therapies. What is the consensus analysts' recommendation for Intra-Cellular Therapies? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about Intra-Cellular Therapies stock? Here are some recent quotes from research analysts about Intra-Cellular Therapies stock: 1. According to Zacks Investment Research, "Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York. " (5/8/2018) 2. Cantor Fitzgerald analysts commented, "Lumateperone NDA filing still expected in mid-2018. We view the pre- NDA meeting (and what may be said thereafter), the actual filing and the FDA acceptance of it (presumably) as minor events that are expected and not stock moving." (3/1/2018) 3. SunTrust Banks, Inc. analysts commented, "Meeting with FDA could help identify the path forward for ralinepag. On the 3Q17 results conference call, management commented that the company will seek a meeting with the FDA to determine the pivotal development plan for ralinepag. Specific timing of the meeting is pending FDA scheduling but management laid out their views on the drug candidate’s development program. Key considerations include 1) accelerating time to market, 2) maximizing the breadth and scope of label, 3) raising physician awareness of the compound and 4) comparing ralinepag with other available treatments." (11/8/2017) Who are some of Intra-Cellular Therapies' key competitors? Some companies that are related to Intra-Cellular Therapies include Madrigal Pharmaceuticals (MDGL), GW Pharmaceuticals (GWPH), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), Array Biopharma (ARRY), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), Amicus Therapeutics (FOLD), The Medicines (MDCO), Blueprint Medicines (BPMC), Ascendis Pharma A/S (ASND), Intercept Pharmaceuticals (ICPT), Horizon Pharma (HZNP), Heron Therapeutics (HRTX) and Emergent Biosolutions (EBS). Who are Intra-Cellular Therapies' key executives? Intra-Cellular Therapies' management team includes the folowing people: Dr. Sharon Mates, Co-Founder, Chairman, CEO & Pres (Age 65)Mr. Lawrence J. Hineline CPA, VP of Fin., CFO, Treasurer & Assistant Sec. (Age 62)Dr. Robert E. Davis, Sr. VP & Chief Scientific Officer (Age 67)Mr. Michael I. Halstead J.D., Sr. VP, Gen. Counsel, Corp. Compliance Officer & Sec. (Age 45)Dr. Andrew Satlin M.D., Exec. VP & Chief Medical Officer (Age 63) Has Intra-Cellular Therapies been receiving favorable news coverage? News stories about ITCI stock have trended somewhat positive on Tuesday, according to Accern Sentiment. The research firm ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Intra-Cellular Therapies earned a news sentiment score of 0.08 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 45.30 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days. Who are Intra-Cellular Therapies' major shareholders? Intra-Cellular Therapies' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Essex Investment Management Co. LLC (0.06%) and Fox Run Management L.L.C. (0.06%). Company insiders that own Intra-Cellular Therapies stock include Alafi Capital Co Llc, Christopher D Alafi, Kimberly E Vanover, Lawrence J Hineline, Michael Halstead, Richard A Lerner, Robert E Davis and Sharon Mates. View Institutional Ownership Trends for Intra-Cellular Therapies. Which institutional investors are buying Intra-Cellular Therapies stock? ITCI stock was purchased by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C. and Essex Investment Management Co. LLC. Company insiders that have bought Intra-Cellular Therapies stock in the last two years include Alafi Capital Co Llc and Christopher D Alafi. View Insider Buying and Selling for Intra-Cellular Therapies. How do I buy shares of Intra-Cellular Therapies? Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Intra-Cellular Therapies' stock price today? One share of ITCI stock can currently be purchased for approximately $20.45. How big of a company is Intra-Cellular Therapies? Intra-Cellular Therapies has a market capitalization of $1.12 billion and generates $250,000.00 in revenue each year. The biopharmaceutical company earns $-97,770,000.00 in net income (profit) each year or ($2.12) on an earnings per share basis. Intra-Cellular Therapies employs 49 workers across the globe. How can I contact Intra-Cellular Therapies? Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 646-440-9333 or via email at [email protected] MarketBeat Community Rating for Intra-Cellular Therapies (NASDAQ ITCI)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 308 (Vote Outperform)Underperform Votes: 207 (Vote Underperform)Total Votes: 515MarketBeat's community ratings are surveys of what our community members think about Intra-Cellular Therapies and other stocks. Vote "Outperform" if you believe ITCI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ITCI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/17/2018 by MarketBeat.com StaffFeatured Article: Should I invest in "strong buy" stocks?